BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesEarnings

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today

Related news

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

TMCITreace Medical Concepts2026-11-06 12:05 EST

Treace Medical Concepts Reports Third Quarter 2026 Financial Results

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

AORTArtivion2026-11-05 21:05 EST

Artivion Reports Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

APYXApyx Medical2026-11-05 12:00 EST

Apyx Medical Corporation Reports Third Quarter 2026 Financial Results

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

PRCTPROCEPT BioRobotics2026-11-04 21:05 EST

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACHCAcadia Healthcare2026-11-04 21:05 EST

Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance

ICUSeaStar Medical2026-11-04 13:41 EST

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-11-04 21:05 EST

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

ADPTAdaptive Biotechnologies2026-09-25 12:03 EST

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Stock data

Close
26.83 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States